Ibrutix

Ibrutix (Ibrutinib) is a kinase inhibitor indicated for the treatment of patients with: Mantle Cell Lymphoma (MCL) who have received at least one prior therapy, Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) with 17p deletion, Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. Ibrutix is available in capsule form for oral administration. Capsules should be taken orally with a glass of water. 

Features